GLP-1 Weight Loss Injection: Ozempic, Mounjaro & Wegovy

GLP-1 receptor agonists are a class of medications originally developed for the treatment of type 2 diabetes. Since 2023, compounds such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become the focus of growing public interest — not least due to their significant effect on body weight. They mimic the endogenous hormone GLP-1 (glucagon-like peptide-1), which is released after eating and regulates both insulin secretion and the feeling of satiety in the brain. The result: less hunger, slower gastric emptying, and reduced calorie intake. What was initially considered a diabetes medication has evolved into one of the most discussed topics in the field of weight medicine.

Overview hide

Ozempic, Mounjaro, Wegovy — What is the Difference?

Ozempic: The Medication Everyone Knows

Mounjaro: The New Star Among Weight Loss Injections

Wegovy: Specifically Approved for Weight Loss

Costs and Availability in Germany

Who is eligible for treatment?

Frequently Asked Questions about GLP-1 Weight-loss Injections

Important Note: All mentioned medications are prescription-only and should only be taken under medical supervision. This article is solely for general information and does not replace medical advice.

Ozempic, Mounjaro, Wegovy — What is the Difference?

At first glance, the names may seem interchangeable, but Ozempic, Mounjaro, and Wegovy contain different active ingredients, approvals, and indications.

Medication	Active Ingredient	Approval in Germany	Use	Cost per Month (approx.)
Ozempic	Semaglutide	Type 2 diabetes	Weekly injection	approx. 100–200 €
Wegovy	Semaglutide (higher dose)	Obesity (BMI ≥30)	Weekly injection	approx. 250–350 €
Mounjaro	Tirzepatide	Type 2 diabetes + obesity	Weekly injection	approx. 200–300 €

All three medications are administered as a subcutaneous injection once per week. The key difference lies in the mechanism: while Ozempic and Wegovy exclusively activate the GLP-1 receptor, Mounjaro also acts on the GIP receptor (glucose-dependent insulinotropic peptide) — a so-called dual agonist.

Ozempic: The Medication Everyone Knows

Ozempic contains the active ingredient semaglutide and is officially approved in Germany for the treatment of type 2 diabetes. The GLP-1 receptor agonist works by increasing insulin secretion, inhibiting glucagon release, and slowing gastric emptying. The delayed digestion process prolongs the feeling of fullness — an effect that helps individuals lose weight.

Ozempic is injected using a prefilled pen. The dosage typically starts at 0.25 mg per week and is gradually increased. The so-called click table indicates how many clicks on the pen correspond to a specific dose — a frequently searched topic for patients who want to optimize their settings. A detailed explanation of the dosage steps and adjustment options can be found here: Ozempic Dosage and Click Table.

Important: Ozempic is not approved in Germany for weight loss without a diabetes diagnosis. Those who use it as a weight loss aid do so off-label and usually bear the costs themselves.

Mounjaro: The New Star Among Weight Loss Injections

Mounjaro, containing the active ingredient tirzepatide, is considered the most effective substance in pharmacological weight therapy to date. As a dual GIP/GLP-1 receptor agonist, tirzepatide simultaneously activates two different hormone receptors, leading to stronger appetite control and greater weight loss compared to simple GLP-1 agonists.

Clinical studies show that patients using Mounjaro can lose up to 22% of their body weight on average — a value significantly higher than that of Ozempic. In Germany, Mounjaro is approved for both type 2 diabetes and obesity. A personal experience report on 30 days of Mounjaro — effects on weight, hunger, and daily life — can be read here: 30 Days of Mounjaro: Experience Report.

Due to high demand, the availability of Mounjaro in pharmacies is not always guaranteed. A medical prescription is mandatory.

Wegovy: Specifically Approved for Weight Loss

Wegovy contains the same active ingredient as Ozempic — Semaglutide — but in a higher dosage (up to 2.4 mg per week). The key difference: Wegovy is explicitly approved in Germany for the treatment of obesity, not diabetes. It is intended for adults with a body mass index (BMI) of at least 30 kg/m² or a BMI of at least 27 kg/m² with at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, dyslipidemia).

Clinical studies show that patients using Wegovy lose an average of 15–17% of their initial weight. Since it is an approval for obesity, Wegovy can be covered by the statutory health insurance under certain conditions — although the hurdle is high and an individual assessment is necessary.

Costs and Availability in Germany

The costs of GLP-1 weight-loss injections vary significantly depending on the medication and dosage. Ozempic costs between 100 and 200 euros per month for self-payers, Wegovy is priced between 250 and 350 euros, and Mounjaro ranges between 200 and 300 euros. For diabetics, Ozempic and Mounjaro may be covered by health insurance under certain circumstances — however, off-label use for pure weight loss is generally not reimbursed.

Another issue is availability: due to the significantly increased demand, there have been repeated supply shortages for Ozempic and Wegovy in recent years. Pharmacies are not always able to procure the desired dosage strength on short notice. Find alternatives and a current price overview here: Ozempic Prices and Alternatives.

Who is eligible for treatment?

GLP-1 weight-loss injections are not lifestyle medications for people who want to lose a few kilograms. They are prescription drugs with clear medical indications and approval criteria:

Ozempic: Indicated for type 2 diabetes, off-label for overweight without a diabetes diagnosis
Wegovy: BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with a comorbid condition
Mounjaro: Type 2 diabetes and obesity (BMI ≥ 30 kg/m²)

In all cases, a medical prescription is required. The treatment should always be combined with a dietary change and physical activity. People with certain pre-existing conditions (e.g., pancreatitis, medullary thyroid carcinoma, severe kidney insufficiency) are excluded from the treatment. A self-experiment without medical supervision is not recommended and medically risky.

Frequently Asked Questions about GLP-1 Weight-loss Injections

What is better — Ozempic or Mounjaro?
Mounjaro shows a greater average weight loss in clinical studies than Ozempic. As a dual GIP/GLP-1 agonist, Tirzepatide acts on two receptors at the same time. Which medication is suitable for someone depends on the treating physician based on the individual diagnosis, medical history, and tolerance.

How quickly do you lose weight with Ozempic?
Weight loss with Ozempic is gradual and depends on the dosage, diet, and exercise. In studies, patients lost an average of between 5 and 15% of their initial weight over a period of 68 weeks. In the first weeks, weight loss is often lower, as the dose is gradually increased.

Is Mounjaro available in Germany?
Yes, Mounjaro is available in Germany and approved — both for type 2 diabetes and obesity. However, it is prescription-only and may not always be in stock in some pharmacies due to high demand. A medical prescription is a prerequisite.

How much does Wegovy cost per month?
Wegovy costs between 250 and 350 euros per month for self-payers in Germany, depending on the dosage level and pharmacy. In individual cases, health insurance may cover the costs if obesity is proven — however, this is not the norm and depends on the individual health situation.